Literature DB >> 15313886

Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer.

Tyler J Curiel1, Pui Cheng, Peter Mottram, Xavier Alvarez, Lieve Moons, Melina Evdemon-Hogan, Shuang Wei, Linhua Zou, Ilona Kryczek, Gary Hoyle, Andrew Lackner, Peter Carmeliet, Weiping Zou.   

Abstract

Angiogenesis is essential for both primary and metastatic tumor growth. Tumor blood vessel formation is complex and regulated by many factors. Ovarian carcinomas have a poor prognosis, often associated with multifocal intraperitoneal dissemination accompanied by intense neovascularization. To examine tumor angiogenesis in the tumor microenvironment, we studied malignant ascites of patients with untreated ovarian carcinoma. We observed high numbers of plasmacytoid dendritic cells (PDCs) and significant stromal-derived factor (CXCL-12/SDF)-1 in their malignant ascites, attracting PDCs into the tumor environment. We now show that tumor-associated PDCs induced angiogenesis in vivo through production of tumor necrosis factor alpha and interleukin 8. By contrast, myeloid dendritic cells (MDCs) were absent from malignant ascites. MDCs derived in vitro suppressed angiogenesis in vivo through production of interleukin 12. Thus, the tumor may attract PDCs to augment angiogenesis while excluding MDCs to prevent angiogenesis inhibition, demonstrating a novel mechanism for modulating tumor neovascularization. Because dendritic cells (DCs) have long been known to affect tumor immunity, our data also implicate DCs in regulation of tumor neoangiogenesis, suggesting a novel role of DCs in tumor pathology.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15313886     DOI: 10.1158/0008-5472.CAN-04-1272

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  89 in total

1.  Oncoantigens for an immune prevention of cancer.

Authors:  Elisabetta Bolli; Elena Quaglino; Maddalena Arigoni; Pier-Luigi Lollini; Raffaele Calogero; Guido Forni; Federica Cavallo
Journal:  Am J Cancer Res       Date:  2010-12-20       Impact factor: 6.166

2.  Papillary thyroid carcinoma behavior: clues in the tumor microenvironment.

Authors:  Kensey Bergdorf; Donna C Ferguson; Mitra Mehrad; Kim Ely; Thomas Stricker; Vivian L Weiss
Journal:  Endocr Relat Cancer       Date:  2019-06       Impact factor: 5.678

3.  Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells.

Authors:  Andrea Facciabene; Xiaohui Peng; Ian S Hagemann; Klara Balint; Andrea Barchetti; Li-Ping Wang; Phyllis A Gimotty; C Blake Gilks; Priti Lal; Lin Zhang; George Coukos
Journal:  Nature       Date:  2011-07-13       Impact factor: 49.962

4.  Plasmacytoid dendritic cells in the tumor microenvironment: immune targets for glioma therapeutics.

Authors:  Marianela Candolfi; Gwendalyn D King; Kader Yagiz; James F Curtin; Yohei Mineharu; A K M Ghulam Muhammad; David Foulad; Kurt M Kroeger; Nick Barnett; Regis Josien; Pedro R Lowenstein; Maria G Castro
Journal:  Neoplasia       Date:  2012-08       Impact factor: 5.715

Review 5.  Innate immunity, decidual cells, and preeclampsia.

Authors:  Chang-Ching Yeh; Kuan-Chong Chao; S Joseph Huang
Journal:  Reprod Sci       Date:  2012-07-18       Impact factor: 3.060

6.  Beneficial effects of sunitinib on tumor microenvironment and immunotherapy targeting death receptor5.

Authors:  Yoko Tsukita; Tatsuma Okazaki; Satoru Ebihara; Riyo Komatsu; Mayumi Nihei; Makoto Kobayashi; Taizou Hirano; Hisatoshi Sugiura; Tsutomu Tamada; Nobuyuki Tanaka; Yasufumi Sato; Hideo Yagita; Masakazu Ichinose
Journal:  Oncoimmunology       Date:  2018-11-13       Impact factor: 8.110

Review 7.  Manipulating the intersection of angiogenesis and inflammation.

Authors:  Brian J Kwee; David J Mooney
Journal:  Ann Biomed Eng       Date:  2014-10-15       Impact factor: 3.934

8.  Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity.

Authors:  Natalia Lapteva; Melissa Aldrich; David Weksberg; Lisa Rollins; Tatiana Goltsova; Si-Yi Chen; Xue F Huang
Journal:  J Immunother       Date:  2009 Feb-Mar       Impact factor: 4.456

9.  Ovarian Cancer: Therapeutic Strategies to Overcome Immune Suppression.

Authors:  Maureen L Drakes; Patrick J Stiff
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 10.  Harnessing the effect of adoptively transferred tumor-reactive T cells on endogenous (host-derived) antitumor immunity.

Authors:  Yolanda Nesbeth; Jose R Conejo-Garcia
Journal:  Clin Dev Immunol       Date:  2010-11-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.